Pharma Reports

The “2025 Exudative Retinal Disease Pharmaceuticals Market Report” delivers a comprehensive analysis of anti-VEGFs and other therapies for exudative retinal diseases. It highlights key market trends, growth drivers, and future opportunities, with five-year forecasts in units and dollars for branded ocular anti-VEGFs, cancer drugs used off-label, biosimilars, and sustained-drug-delivery devices. The report also breaks down market share by product category and profiles 29 leading competitors, detailing their products, strategies, and market positioning. 

The “2025 Nonexudative Retinal Disease Pharmaceuticals Market Report” delivers a comprehensive analysis of current and emerging therapies for geographic atrophy, dry AMD, and other nonexudative retinal diseases. It evaluates complement inhibitors, gene therapies, sustained-release technologies, antioxidants, and more—examining key market trends, patient economics, reimbursement dynamics, and five-year growth forecasts.  

The report also includes detailed unit and dollar demand projections, product category market shares, and profiles of 19 leading competitors with insights into their strategies and outlooks. 

The “2025 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2030 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 25 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook. 

The “2023 US and Western Europe Cataract Pharmaceuticals Market Report” offers an in-depth examination of the current cataract pharmaceuticals market in the United States and Western Europe and forecasts market performance over the next five years. The report analyzes the current market and forecasts units, average sales price, and revenue through 2028 by product category. It analyzes products currently on the market and examines the development pipeline, discusses the popularity of intracameral injections and fixed combination eye drops, and analyzes the roles of brand name medications, generics, and compounded formulations.